Antigen-Amplifying mRNA Vaccine & CAR-T Development Service for Solid Tumor Targeting

While CAR-T therapy has achieved remarkable success in hematologic malignancies, its efficacy in solid tumors remains limited by critical barriers including antigen heterogeneity, poor T cell persistence, and immunosuppressive tumor microenvironments. To address these challenges, Creative Biolabs' Antigen-Amplifying mRNA Vaccine & CAR-T Development Service for Solid Tumor Targeting synergistically enhances CAR-T function through rationally designed mRNA vaccine boosts. Our platform leverages proprietary LNP delivery technology and mechanism-driven antigen spreading strategies to promote sustained T cell activation and broaden antitumor immune responses.

Introduction

An Antigen-Amplifying mRNA Vaccine is an innovative immunotherapeutic strategy designed to enhance and sustain T cell responses by repeatedly presenting target antigens to the immune system, thereby promoting robust T cell expansion and functional persistence. The integration of such vaccines with CAR-T cell therapy is of critical importance, as it directly addresses key limitations in solid tumor treatment, including inadequate T cell persistence, antigen escape, and tumor heterogeneity, enabling a more potent, durable, and broadened antitumor immune response.

Fig.1 Key benefits of mRNA-based vaccines for cancer immunotherapy.¹

Antigen-Amplifying mRNA Vaccine & CAR-T Development Service for Solid Tumor Targeting at Creative Biolabs

Creative Biolabs' Antigen-Amplifying mRNA Vaccine & CAR-T Development Service for Solid Tumor Targeting leverages mRNA vaccine technology to drive antigen spreading, effectively overcoming tumor heterogeneity and antigen escape. Through a non-viral delivery system, we enable transient yet efficient CAR expression with enhanced safety profiles. Our platform addresses the dual challenges of immune response breadth and durability in solid tumor treatment, delivering an end-to-end innovative solution.

What We Can Offer

Our integrated service provides a comprehensive suite of solutions for solid tumor immunotherapy, combining antigen-amplifying mRNA vaccine technology with non-viral CAR-T development. We offer specialized LNP delivery systems, mechanism-driven antigen spreading strategies, and scalable production platforms to overcome tumor heterogeneity and enhance therapeutic persistence

Our Service Process

Required Starting Materials:

• The specific Target Antigen Sequence(s) (for both the CAR and the vaccine).
• Your preferred CAR Construct Design/Sequence (e.g., scFv sequence, co-stimulatory domains).
• The desired Pre-Clinical Tumor Model Specifications (e.g., cell lines for heterogeneous models, species).

Key steps:

Final Deliverables:

• Final Optimized mRNA-LNP Formulation Protocol.
• Associated Quality Control data.

Key Advantages

• Integrated, End-to-End Solutions: We offer a seamless, one-stop development pathway from target and CAR design through to clinical trials. Our integrated approach streamlines project management, reduces coordination overhead, and significantly accelerates your path to the clinic.
• Proprietary Antigen Spreading Engine: Our platform is uniquely designed to harness the synergy between CAR-T cells and mRNA vaccination. We engineer the immune response to initiate broad Antigen Spreading, effectively addressing tumor heterogeneity and countering antigen escape, keys to achieving durable remission.
• De-Risked, Non-Viral CAR Platforms: By employing transient mRNA-based CAR expression, we eliminate the risk of genomic integration and associated long-term safety concerns.

FAQ

Why Choose Us?

We provide integrated solutions to overcome the core challenge of solid tumors—heterogeneity. Our service uniquely combines a mechanism-driven design that programs CAR-T cells to induce broad antigen spreading with a proprietary LNP platform for precise, transient in vivo engineering. This results in a potent, sustained anti-tumor immune response, accelerated development timelines, and a superior safety profile.

Customer Reviews

"Using Creative Biolabs' Antigen-Amplifying mRNA Vaccine & CAR-T Development Service in our research has significantly improved the in vivo persistence metrics of our lead CAR T candidate, extending median survival in murine models by over 60 days. The LNP formulation was remarkably stable." Dr. Aran.

"The team's expertise in the IFN-γ/Antigen Spreading pathway was invaluable. We solved our antigen-loss problem, a major barrier in our breast cancer program, by using their mRNA boost, which effectively recruited endogenous T cells to clear heterogeneous lesions." Dr. L***ee.

"We chose Creative Biolabs for the non-integrating mRNA CAR option. Their platform facilitated rapid, scalable production and eliminated our concerns about insertional mutagenesis, which sped up our safety package dramatically compared to our previous viral vector approach." Dr. Jobs.

How to Contact Us?

Creative Biolabs is dedicated to accelerating your path to groundbreaking solid tumor immunotherapies. By integrating the cutting-edge science of mRNA programming with the clinical potential of CAR-T cells, we offer a robust, scalable, and mechanism-driven solution to overcome the most challenging limitations in the field.

Partner with us to advance your solid tumor CAR-T program.

Reference

1. Wang, Bolin et al. "Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities." Frontiers in immunology vol. 14 1246682. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2023.1246682.